Nanoparticle Platform with Extensive Patent Coverage.

...with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. A competing nanoparticle company is Nanosphere (NASDAQ: NSPH; $300 MM market cap). However, in contrast to Nanosphere, Minerva’s nanoparticles address a much larger market and do not require the use of expensive, dedicated equipment for analysis. Since the second year of operations the Company has focused squarely on drug discovery and diagnostics for cancer and has used its nanotechnology in-house to expedite the process. Minerva is finalizing a research and development agreement with a leading US based diagnostic company to facilitate shared development of the technology. The agreement should generate an early revenue stream for Minerva as well as drive market awareness of the need for Minerva’s molecularly targeted anti-cancer therapeutics.

E-mail: info@minervabio.com